Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting - Light Version

NCT06488170 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT06488170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06488170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting - Light Version
Lead sponsor
Almirall, S.A.
Phase
Observational
Overall status
Active, not recruiting
Start date
April 4, 2024
Completion date
January 31, 2026
Enrollment
42 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis